Associated tags: Euronext Paris, GBT, Research, AI, Guerbet, Medical imaging, MRI, Pharmaceutical industry, European Medicines Agency, Agent handling
Locations: VILLEPINTE, NORTH AMERICA, AMERICAS, NEW JERSEY, SWITZERLAND, ITALY, UNITED KINGDOM, GERMANY, FR, AUSTRIA, BELGIUM, NETHERLANDS, RALEIGH, NORTH CAROLINA, CHICAGO, FRANKREICH, EU, CHINA, UK, UNITED STATES, ASIA, FRANCE, SPAIN, EUROPE
Retrieved on:
Wednesday, April 10, 2024
CER,
MRI,
Guerbet,
Growth,
Medical imaging,
Prostate,
WCR,
Software,
IBM,
Bank statement,
IBM Watson,
Iodine,
Depreciation,
NB,
Liver,
Artificial intelligence The Group’s operating income came to €38.7m in 2023, compared with a loss of €18.2m the previous year.
Key Points:
- The Group’s operating income came to €38.7m in 2023, compared with a loss of €18.2m the previous year.
- At 31 December 2023, Guerbet's net income stood at €22.2m, compared with a loss of €41.1m in 2022.
- Free cash flow for full-year 2023 stood at -€65.4m, having entered positive territory in the second half at +€6.6m.
- Financially, after comfortably achieving the business and profitability targets it had set for 2023, the Group is looking to 2024 with increased confidence.
Retrieved on:
Wednesday, April 10, 2024
Financial management,
Supervisory board,
Trust,
Central nervous system,
Patient,
GBT,
Sanofi,
Hospital,
Mass meeting,
Audit committee,
MBA,
OTC,
BPI,
Management Guerbet: Change in Guerbet’s Board of Directors.
Key Points:
- Guerbet: Change in Guerbet’s Board of Directors.
- Hugues Lecat’s appointment as a director will be submitted for approval at the next Shareholders’ Meeting.
- The management experience acquired by Hugues in large companies in the pharmaceutical sector will help guide the Group in achieving further success.
- Hugues was also a member of the Board of Directors of NOVASEP on behalf of BPI between 2012 and 2017.
Retrieved on:
Wednesday, March 13, 2024
Senior,
GBT,
Corporate communication,
Marketing,
Commerce,
Hemostasis,
Government,
Executive Committee,
Thrombosis,
Human resources,
Public affairs,
Communication,
IVD Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.
Key Points:
- Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.
- Villepinte, 11 march 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the strengthening of its management team with two appointments.
- Christine Allard and Eva Ohlsson have joined the Group as senior Vice-President Public Affairs and Corporate Communications, and Senior Vice President Human Resources respectively.
- Reporting directly to David Hale, Chief Executive Officer, they will both become members of Guerbet’s Executive Committee.
Retrieved on:
Thursday, February 8, 2024
The Diagnostic Imaging division posted revenue growth of 6.3 % at CER in 2023.
Key Points:
- The Diagnostic Imaging division posted revenue growth of 6.3 % at CER in 2023.
- X-ray sales grew 7% in 2023 at CER, thanks to the robust sales trend of Xenetix®, which offset the decline in Optiray®revenues; this trend reversed in the fourth quarter of 2023, a period marked by growth for the entire X-ray division of 12.5% at CER.
- For the 2023 financial year, after meeting its sales growth target, Guerbet will achieve a restated EBITDA margin rate3 higher than the 11% expected.
- This objective is now largely supported by the favourable change in the product mix as well as cost control observed in the fourth quarter of 2023.
Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years.
Key Points:
- Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years.
- The Group is deeply saddened to announce the death of Michel Guerbet, who passed away on January 23, 2024 at the age of 92.
- An historic figure in the Guerbet Group, Michel Guerbet was the son of André, who founded the laboratory in 1926, and the grandson of Marcel, who co-developed Lipiodol® in 1901.
- The family is fully committed to supporting the Group in its operational development and the achievement of its medium- and long-term strategic objectives.
Retrieved on:
Monday, December 11, 2023
Syringe,
Safety,
Regulatory affairs,
European Medicines Agency,
Aulnay-sous-Bois,
European Commission,
Ageing,
GBCA,
Gadolinium,
Civil service commission,
Medicine,
European,
FDA,
CHMP,
BBB,
Marketing,
Committee,
Pathology,
Marans, Charente-Maritime,
Person,
Medical imaging,
Seine-Saint-Denis,
MRI,
Radiology The marketing authorisation (MA) for Elucirem™ (Gadopiclenol) was granted to Guerbet by the European Commission based on the positive opinion of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dated 12 October 2023.
Key Points:
- The marketing authorisation (MA) for Elucirem™ (Gadopiclenol) was granted to Guerbet by the European Commission based on the positive opinion of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dated 12 October 2023.
- It will be marketed by Guerbet in the European Union in the following forms: vials and prefilled syringes.
- "After its approval by the FDA for the American market, the European marketing authorisation for Elucirem™ reinforces our strategic perspective: combining medical innovation and environmental commitment.
- This authorisation is ground-breaking for Medical Imaging in Europe," concludes David Hale, Guerbet CEO.
Retrieved on:
Monday, November 27, 2023
University of Colorado Denver,
South Hall (UC Berkeley),
Relaxation,
Glomerular filtration rate,
Fractional dose vaccination,
Blood,
University,
Guerbet,
Doctor of Philosophy,
Risk,
MRI,
AI,
Radiology,
CST,
Medical imaging,
MD,
Vitro PRINCETON, N.J., Nov. 27, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today its schedule of activities at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL. In addition to the Guerbet exhibit (booth #1711), the company will be presenting safety data in an abstract titled "Safety of gadopiclenol for magnetic resonance imaging (MRI): a pooled analysis of eight studies." The session number W3-STCE1, will be presented as a scientific session on Wednesday, November 29 at 10:00-10:30 a.m. CST.
Key Points:
- Jeffrey H Maki, MD, PhD, Professor of Radiology and Director of MRI at the University of Colorado in Denver will be presenting "Relaxation properties of GBCAs In Vitro, in human blood – their unique behavior might surprise you" at 1:00 p.m. CST on Monday, November 27th.
- This presentation, which will take place in the RSNA Innovation Theater Exhibitor Pavillion in the South Hall, is based on a study done to measure T1 and T2 relaxivity In Vitro, in human blood.
- In addition to showcasing diagnostic and interventional solutions, Guerbet will also feature its digital and AI software-based products that help to close the loop with the smart connectivity between monitoring and reporting.
- Products that will be featured include:
Contrast & Care®, an injection data management solution that enables imaging centers to collect, archive, examine, and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate, and other risk factors before a clinical exam
Optistar™ Elite, a dual head contrast delivery system with an ultrasonic motor that makes it non-magnetic, built for long lasting performance and now has the new Fractional Dosing capabilities
Retrieved on:
Thursday, November 2, 2023
MRI,
CST,
University of Colorado Denver,
Radiology,
South Hall (UC Berkeley),
Doctor of Philosophy,
Glomerular filtration rate,
Guerbet,
Relaxation,
Risk,
Fractional dose vaccination,
University,
Blood,
AI,
Medical imaging,
MD,
Vitro PRINCETON, N.J., Nov. 2, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today its schedule of activities at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL. In addition to the Guerbet exhibit (booth #1711), the company will be presenting safety data in an abstract titled "Safety of gadopiclenol for magnetic resonance imaging (MRI): a pooled analysis of eight studies." The session number W3-STCE1, will be presented as a scientific session on Wednesday, November 29 at 10:00-10:30 a.m. CST.
Key Points:
- Jeffrey H Maki, MD, PhD, Professor of Radiology and Director of MRI at the University of Colorado in Denver will be presenting "Relaxation properties of GBCAs In Vitro, in human blood – their unique behavior might surprise you" at 1:00 p.m. CST on Monday, November 27th.
- This presentation, which will take place in the RSNA Innovation Theater Exhibitor Pavillion in the South Hall, is based on a study done to measure T1 and T2 relaxivity In Vitro, in human blood.
- In addition to showcasing diagnostic and interventional solutions, Guerbet will also feature its digital and AI software-based products that help to close the loop with the smart connectivity between monitoring and reporting.
- Products that will be featured include:
Contrast & Care®, an injection data management solution that enables imaging centers to collect, archive, examine, and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate, and other risk factors before a clinical exam
Optistar™ Elite, a dual head contrast delivery system with an ultrasonic motor that makes it non-magnetic, built for long lasting performance and now has the new Fractional Dosing capabilities
Retrieved on:
Thursday, October 12, 2023
III,
European,
European Commission,
Committee for Medicinal Products for Human Use,
CHMP,
Radiology,
Agent handling,
Brain,
Breast,
Pancreas,
Medicine,
Central nervous system,
Liver,
Magnetic resonance imaging,
European Medicines Agency,
Spine,
EMA,
FDA,
Kidney,
Committee,
Lung,
Human,
MRI,
Tissue,
Civil service commission,
CNS,
Prostate,
Gadolinium,
Patient,
Regulatory affairs,
Medical imaging,
Health,
EU Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.
Key Points:
- Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.
- Villepinte, France, 12 october 2023: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion concerning the granting of a marketing authorisation for Elucirem™ (Gadopiclenol) in the European Union (EU) for use in adults and children aged 2 years and over for MRI with contrast enhancement.
- The positive opinion from the CHMP is essentially based on data from two phase III clinical trials completed in March 2021.
- "This positive opinion from the CHMP,
at the end of 2023, will bring European patients and health professionals
Retrieved on:
Wednesday, September 20, 2023
Tax,
CER,
Bank statement,
European Directive on Traditional Herbal Medicinal Products,
Agent handling,
WCR,
Committee,
MRI,
Guerbet,
EBITDA,
Algorithm,
Artificial intelligence,
Depreciation,
Growth,
Liver,
Committee for Medicinal Products for Human Use,
Iodine,
Disease,
CHMP,
Cryptocurrency As indicated when the annual results were published, Guerbet's 2023 operational profitability is subject to a context in which costs are rising more sharply than in the previous fiscal year.
Key Points:
- As indicated when the annual results were published, Guerbet's 2023 operational profitability is subject to a context in which costs are rising more sharply than in the previous fiscal year.
- As of 30 June 2023, the Group's operating income was €10.3 million, compared to €16.9 million one year earlier.
- In terms of profitability, inflationary pressures (in particular for iodine) will continue to be felt in the second half of 2023.
- In this context, Guerbet confirms that it anticipates revenue growth of more than 5% on a like-for-like basis and at CER in 2023.
